{"id":"NCT00964158","sponsor":"GlaxoSmithKline","briefTitle":"Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","officialTitle":"Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-10","primaryCompletion":"2010-11-27","completion":"2010-11-27","firstPosted":"2009-08-24","resultsPosted":"2018-02-19","lastUpdate":"2018-02-19"},"enrollment":210,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Pandemic influenza vaccine GSK2340272A","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"}],"summary":"This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.","primaryOutcome":{"measure":"Number of Subjects With Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value","timeFrame":"At Day 0","effectByArm":[{"arm":"GSK2340272A Group","deltaMin":40,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":5,"countries":["Spain"]},"refs":{"pmids":["26176592","21504774"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["Pain","Swelling","Headache","Fatigue","Pyrexia"]}}